Inhibition of mTORC1 with rapamycin was recently demonstrated to slow the progression of mitochondrial myopathy in mouse models by improving several hallmarks of mitochondrial dysfunction, resulting in reduced expression of Atf4, Fgf21, mitochondrial chaperones and key enzymes of the 1C pathway (Khan et al., 2017). The gene discussed is ATF4; the disease is Mitochondrial myopathy.